Figure 3From: Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapyp-AKT (A; pLR n = 43, pMR n = 13, pCR n = 12) and p-ERK (B; pLR n = 44, pMR n = 12, pCR n = 12) expression by radiation response (residual disease at the time of surgery) with responses categorized as limited response (pLR), major response (pMR), or complete response (pCR).Back to article page